WELLBUTRIN XL Drug Patent Profile
✉ Email this page to a colleague
When do Wellbutrin Xl patents expire, and when can generic versions of Wellbutrin Xl launch?
Wellbutrin Xl is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in WELLBUTRIN XL is bupropion hydrochloride. There are thirty-eight drug master file entries for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Wellbutrin Xl
A generic version of WELLBUTRIN XL was approved as bupropion hydrochloride by APNAR PHARMA LP on February 7th, 2000.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for WELLBUTRIN XL?
- What are the global sales for WELLBUTRIN XL?
- What is Average Wholesale Price for WELLBUTRIN XL?
Summary for WELLBUTRIN XL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 138 |
Clinical Trials: | 85 |
Patent Applications: | 1,189 |
Drug Prices: | Drug price information for WELLBUTRIN XL |
What excipients (inactive ingredients) are in WELLBUTRIN XL? | WELLBUTRIN XL excipients list |
DailyMed Link: | WELLBUTRIN XL at DailyMed |
Recent Clinical Trials for WELLBUTRIN XL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Pfizer | Phase 1 |
Mclean Hospital | Phase 4 |
National Cancer Institute (NCI) | Phase 4 |
Pharmacology for WELLBUTRIN XL
Drug Class | Aminoketone |
Mechanism of Action | Dopamine Uptake Inhibitors Norepinephrine Uptake Inhibitors |
Physiological Effect | Increased Dopamine Activity Increased Norepinephrine Activity |
Paragraph IV (Patent) Challenges for WELLBUTRIN XL
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
WELLBUTRIN XL | Extended-release Tablets | bupropion hydrochloride | 150 mg and 300 mg | 021515 | 1 | 2004-09-21 |
US Patents and Regulatory Information for WELLBUTRIN XL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch | WELLBUTRIN XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021515-001 | Aug 28, 2003 | AB3 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Bausch | WELLBUTRIN XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021515-002 | Aug 28, 2003 | AB3 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for WELLBUTRIN XL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch | WELLBUTRIN XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021515-001 | Aug 28, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Bausch | WELLBUTRIN XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021515-002 | Aug 28, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Bausch | WELLBUTRIN XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021515-002 | Aug 28, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Bausch | WELLBUTRIN XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021515-001 | Aug 28, 2003 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |